MP Corporation, "Kovivac Maintains Antibodies for 1 Year Without Side Effects"... Published in International Academic Journal

[Asia Economy Reporter Jang Hyowon] The antibody formation research results of the Russian COVID-19 vaccine 'Covivak,' whose domestic production is being accelerated by MP Corporation (MPCO) and DA Technology, have been published in an internationally prestigious academic journal.

MPCO announced on the 31st that a paper on the clinical study of the stability and durability of the Covivak vaccine was published in the recent issue of 'Emerging Microbes & Infections. 2021,' published by Nature Publishing Group (NPG), which publishes the world-renowned journal Nature.

This paper contains research results proving the long-term humoral immunogenicity, stability, and efficacy of Covivak, an inactivated vaccine.

According to the paper, when Covivak was administered to preclinical experimental subjects, no specific toxicity or allergic side effects were observed, and neutralizing antibodies in the blood increased. In particular, antibodies formed by vaccination were maintained for about one year, and antibody formation in the blood was confirmed to be uniformly maintained across all batches.

Additionally, in animal experiments involving mice, guinea pigs, and clinical trials on non-human primates such as marmosets (monkeys), administering a high dose of the vaccine twice resulted in an increase in neutralizing antibodies in the blood. Compared to the placebo group, a reduction in virus quantity was observed in nasopharyngeal and rectal swab samples and lung tissues of the vaccine group, and lung tissue lesions decreased between days 4 and 7 after viral infection.

Covivak received conditional use approval from the Russian government last February and has already entered commercialization in Russia. Currently, phase 3 clinical trials are underway with about 30,000 participants, and a preliminary review application for product approval has been submitted to the Korean Ministry of Food and Drug Safety, with preparations for production and distribution in progress.

Covivak, the third vaccine developed in Russia, is an 'inactivated vaccine' that induces an immune response by injecting viruses killed by heat or chemical methods, unlike the virus vector vaccines and recombinant protein vaccines previously approved for domestic use. Therefore, it is the most classical vaccine platform, with fewer side effects and excellent efficacy against variant viruses, leading to growing interest in inactivated vaccines.

A company official stated, "Covivak has already been verified for excellent safety and immunogenicity in phase 1/2 clinical trials," adding, "The publication in a prestigious academic journal further proves Covivak's efficacy and is expected to play a positive role in phase 3 clinical trials and WHO approval efforts."

He continued, "Despite the global acceleration of vaccine administration, supply imbalances still exist, and booster shot administration is being discussed," adding, "MPCO is already promoting bioreactor supply with DA Technology and will do its best to expedite domestic production and supply of Covivak both domestically and internationally through government and related agency approval procedures."

Meanwhile, Emerging Microbes & Infections is a partner journal of Nature Publishing Group (NPG) and is a world-renowned scientific journal related to microbiology, with an impact factor (IF) of 5.84, mainly introducing excellent papers on emerging infectious diseases.

This content was produced with the assistance of AI translation services.